US-based specialty pharmaceutical company, Bentley Pharmaceuticals, has received US Patent and Trademark Office recognition through the award of patent number 7,244,703 entitled "Pharmaceutical Compositions and Methods for Peptide Treatment."
The patent extends coverage for Bentley's current intranasal drug delivery technology employing CPE-215 beyond insulin to include delivery of other therapeutically effective, pharmaceutically active peptides, peptidomimetics and proteins.
In September 2006, Bentley received a US patent covering its intranasal delivery spray for insulin.
The new patent, which was issued from an application filed back in 2004, provides proprietary protection to Bentley for 20 years from the date of filing.
Our goal is to identify and embed transformational patient insights as a fundamental part of the drug development process. As...